Cargando…

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience

PURPOSE: Lymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage. A broadly accepted standard treatment for adult LBL has not yet been defined. MATERIALS AND METHODS: To address this issue, we compared two chemotherapy regimens: a modified non-Hodgkin lymphoma Berl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chun, Wuxiao, Zhi-Jun, Chen, Xiaoqin, Chen, Guanjun, Lu, Yue, Xia, Zhongjun, Liang, Yang, Wang, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176963/ https://www.ncbi.nlm.nih.gov/pubmed/32019289 http://dx.doi.org/10.4143/crt.2019.542

Ejemplares similares

Progression of a hepatosplenic gamma delta T‐cell leukemia/lymphoma on hyperCVAD/MTX and ara‐C: literature review and our institutional treatment approach
por: Saste, Abhijit, et al.
Publicado: (2015)

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG
por: Linder, Katherine, et al.
Publicado: (2016)

Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
por: Ryu, Il Hwan, et al.
Publicado: (2015)

Effectiveness of modified hyper‐CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience
por: Jalaeikhoo, Hasan, et al.
Publicado: (2018)

Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
por: Malakoutikhah, Zahra, et al.
Publicado: (2023)

Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia
por: Cai, Bo, et al.
Publicado: (2022)

Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
por: Brunvand, Mark W., et al.
Publicado: (2017)

Retinal and Preretinal Hemorrhages in a Patient Receiving Hyper-CVAD Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
por: Peddada, Krishi, et al.
Publicado: (2018)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia
por: Tran, Phu Ngoc, et al.
Publicado: (2017)

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy
por: Law, Man Fai, et al.
Publicado: (2021)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Outcome of ALL With ALL-BFM-95 Protocol in Nepal
por: Sharma Poudyal, Bishesh, et al.
Publicado: (2023)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen
por: Yu, Hui, et al.
Publicado: (2022)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

The Use of R-Hyper-CVAD in a Rare Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma
por: Reed, Allison, et al.
Publicado: (2019)

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
por: Sonnevi, Kristina, et al.
Publicado: (2021)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
por: Abla, Dima, et al.
Publicado: (2022)

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib
por: DeRon, Nathan, et al.
Publicado: (2022)

Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen
por: Kroll, Mirko, et al.
Publicado: (2020)

The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG
por: Dalle, Jean-Hugues, et al.
Publicado: (2020)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment
por: Piatopoulou, Despina, et al.
Publicado: (2017)

ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol
por: Wang, Yu, et al.
Publicado: (2018)

Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia
por: Schieck, Maximilian, et al.
Publicado: (2020)

Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols
por: Ampatzidou, Mirella, et al.
Publicado: (2021)

Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol
por: Jung, Mareike, et al.
Publicado: (2020)

Hyper-CVAD/MA方案与CHALL-01方案治疗60岁以下成人Ph阳性急性淋巴细胞白血病的疗效分析
Publicado: (2019)

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Stem cell hunt in NHL
por: Merkel, Olaf, et al.
Publicado: (2015)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
por: Rizzari, Carmelo, et al.
Publicado: (2019)

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group
por: Junk, Stefanie V., et al.
Publicado: (2023)

Outcomes of both abbreviated hyper‐CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10‐year single‐centre experience with literature review
por: Alwasaidi, Turki Abdulaziz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qb05i8hipvvbbppsdhv3h9mgqa